What investors would test, and what we built.

The challenge

A well-protected asset with published preclinical data, a recognized clinical lead and written interest from a pharma company. The deck opened with regulatory detail, and the strongest credibility points arrived near the end.

What investors would test

• Is the regulatory pathway a real shortcut, or a risk?
• Who would partner on this, and why now?
• Can a generalist investor follow the clinical data?

What we built

A reordered narrative that leads with the problem and the evidence, condensed clinical slides for a mixed audience, slide-by-slide rewrites and a tiered investor shortlist.

What changed

The team went into a pitch competition the following week leading with the problem, the data and the partner interest, instead of the regulatory background.

The challenge

A strong preclinical package, including head-to-head results against standard of care, and well-known early investors. The deck had no ask, no competitive landscape and no exit path, and moved between a broad platform and a single lead indication.

What investors would test

• Is this a platform or a product, and what does the Series A buy?
• Why did earlier approaches to this biology fall short?
• Who acquires or partners at the next inflection?

What we built

A new deck architecture that leads with the lead indication and frames the platform as upside, a competitive landscape against first-generation approaches, an ask tied to milestones, and a list of specialist funds.

What changed

One coherent story: a lead program investors can underwrite, and a platform that explains why they should stay for the next round.

The challenge

Granted patents and real policy traction, but two different raise amounts in the same deck, and revenue projections that ran ahead of the clinical and regulatory evidence.

What investors would test

• How big is the first market, really?
• What exactly does this round prove?
• Which claims survive diligence?

What we built

A reconciled ask, projections rebuilt on defensible assumptions, a tighter bottom-up market size, and a list of claims to substantiate or remove.

What changed

A deck and a set of numbers that tell the same story, ready for medtech seed investors and hospital system venture arms.

The challenge

Strong founder-market fit and two signed pilots, but the deck, one-pager and outreach note used different numbers, and the round needed a check against the stage.

What investors would test

• Is the traction real, and will pilots convert?
• How does this win against a well-funded adjacent player?
• Is the round sized and priced for the stage?

What we built

One set of figures across every document, traction reframed around the pilots, sharper positioning against the adjacent player, and a pressure test of round size and valuation.

What changed

Materials ready for vertical AI, techbio and enterprise software investors who understand regulated buyers.